AHA survey: Drug companies reduce access to care by limiting 340B community pharmacies

Nov 14, 2022 - 02:50 PM
340B pic

The AHA today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country. The report is based on a survey of more than 300 hospitals and health systems participating in the 340B program conducted earlier this year by the AHA.

Federally authorized arrangements between 340B hospitals and community and specialty pharmacies are a critical component of the 340B program that allow providers to expand access to many drugs — including those used to treat rare and complex conditions such as some cancers — for the patients and communities they serve.

According to the study:

  • The average 340B critical access hospital reported annualized losses of approximately $507,000, and the average disproportionate share hospital reported annualized losses of nearly $3 million.
  • On average, CAHs reported 44% of their total 340B savings coming from community and specialty pharmacies, with several CAHs reporting that their entire 340B savings come from these arrangements.
  • Overall, 10% of responding hospitals reported average annualized losses of $10 million or more, illustrating the magnitude of the harm that drug companies’ actions have on 340B hospitals and their ability to care for their patients.

“This important new report shows how unlawful actions by drug companies to restrict 340B discounts to community and specialty pharmacies are directly reducing access to care and services for patients and communities, especially those in rural areas,” said AHA Executive Vice President Stacey Hughes. “Drug companies are limiting discounts that help hospitals provide free care for uninsured patients, services in mental health clinics and many community health programs. To protect access to care, we continue to urge the Department of Health and Human Services to aggressively use all tools available to stop these harmful tactics from drug companies.”

Related News Articles

Headline
AHA comments on CY 2026 OPPS proposed rule
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Headline
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models 
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
AHA comments to HRSA on proposed 340B rebate model program
The AHA Aug. 27 said the Health Resources and Services Administration should abandon its 340B Rebate Model Pilot Program.“It is a ‘solution’ in search of a…
Headline
AHA, others urge HRSA to extend timeline for comments and feedback on 340B pilot program
The AHA, joined by several other national groups representing 340B hospitals, Aug. 8 urged the Health Resources and Services Administration to extend the…
Headline
AHA defends HHS decision to reject 340B rebate models by drug companies
The AHA today filed an amicus brief in the U.S. Court of Appeals for the D.C. Circuit, defending the Department of Health and Human Services’ decision to…